Tiziana Life Sciences Ltd (TLSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,746 | -17,242 | -15,397 | -26,657 | -28,338 |
| Depreciation Amortization | 124 | 96 | 51 | 141 | 91 |
| Other Working Capital | -552 | -1,582 | -1,164 | -773 | -295 |
| Other Operating Activity | 15,648 | 3,030 | -3,105 | 5,527 | 17,207 |
| Operating Cash Flow | $-1,526 | $-15,698 | $-19,615 | $-21,762 | $-11,335 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -19 | N/A | N/A | -22 | -3 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -120 |
| Purchase Of Investment | N/A | -1,000 | -2,676 | N/A | N/A |
| Other Investing Activity | -52 | -253 | -1,320 | 152 | 0 |
| Investing Cash Flow | $-71 | $-1,253 | $-3,996 | $130 | $-123 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 163 |
| Common Stock Issued | 4,646 | 159 | N/A | 129 | 75,460 |
| Other Financing Activity | -141 | -119 | -55 | -152 | -277 |
| Financing Cash Flow | $4,505 | $40 | $-55 | $-23 | $75,346 |
| Exchange Rate Effect | -367 | -28 | -398 | -1,983 | 1,736 |
| Beginning Cash Position | 1,183 | 18,122 | 42,186 | 65,824 | 200 |
| End Cash Position | 3,724 | 1,183 | 18,122 | 42,186 | 65,824 |
| Net Cash Flow | $2,541 | $-16,939 | $-24,064 | $-23,638 | $65,624 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,526 | -15,698 | -19,615 | -21,762 | -11,335 |
| Capital Expenditure | -19 | N/A | N/A | -22 | -3 |
| Free Cash Flow | -1,545 | -15,698 | -19,615 | -21,784 | -11,338 |